

**SUPPLEMENT TO BBS-BIOACTIVE BONE SUBSTITUTES PLC'S INVESTOR MEMORANDUM DATED  
26 AUGUST 2024**

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE USA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND OR SOUTH AFRICA OR ANY OTHER JURSDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION IS UNLAWFUL.

BBS-Bioactive Bone Substitutes Plc ("**BBS**" or the "**Company**") supplements the Company's investor memorandum dated 26 August 2024 (the "**Investor Memorandum**") relating to its rights issue with the information set out below. The information below shall be read together with the Investor Memorandum.

**Supplements to the Investor Memorandum**

The Investor Memorandum is supplemented with the following information:

**On 30 August 2024, the Company has announced that it has received subscription undertakings in the amount of approximately EUR 0.4 million.**

As a result of the supplement, the following amendments are made to the Investor Memorandum. Changed information is indicated by underlining where applicable.

The risk description below in pages 22 of the Investor Memorandum is amended to read as follows:

*The Offering may fail to raise the proposed funds in full, and if the funds raised with the Offering are substantially less than expected, this will affect the Company's ability to use the proceeds as planned*

There is no certainty that the Offering will be fully subscribed. The Company has received subscription undertakings from existing shareholders to a total of about EUR 0.4 million. Thus, the parties who have submitted subscription undertakings have committed to subscribe a total of about 16.9 % of the Offering (see section "Terms and conditions of the Offering – Subscription undertakings" of the Investor Memorandum). The Company has neither received nor requested collateral from parties who have committed to subscribing Offer Shares in the Offering on the basis of their subscription undertakings. Although the Company trusts the parties from whom it has received subscription undertakings, there is no certainty that all the parties submitting subscription undertakings will meet their obligations to the Company. If not all parties submitting subscription undertakings do not fulfil their obligations towards the Company, the Company may be obliged to take legal action, which will cause costs and delays in receiving these payments. In such a scenario, the Company may also not gain as much funds from the Offering as would be the case if all the aforementioned parties were to fulfil their obligations according to their agreements.

If a significantly lower amount of funds is raised with the Offering than expected, this would affect the Company's ability to use the proceeds in a planned manner, which may cause delays in commencement of production, marketing and sales. For this reason, the market price of the Company's shares could drop below the Subscription Price of the Offering. In these conditions, investors who have participated in the Offering by subscribing Offer Shares, may suffer a direct unrealised loss as a result of their investment.

Section "Subscription undertakings" is added to page 25 of the Investor Memorandum as follows:

**Subscription undertakings**

Certain current shareholders of the Company mentioned below have provided subscription undertakings, on the basis of which they have committed to subscribe for approximately 16.9 percent of the Offer Shares offered in the Offering, i.e. they have committed to participate in the Offering with approximately 0.4 million euros. The Company has received the following subscription undertakings to subscribe for Offer Shares in connection with the Offering:

<b>Shareholder subscribing for Offer Shares</b>	<b>Subscription undertaking (shares)</b>	<b>Subscription undertaking (EUR)</b>
---	--	---------------------------------------

Panvest Oy	521,836	151,332.44
Finha Capital Oy	362,068	104,999.72
Riverfort Global Opportunities PCC Limited	258,620	74,999.80
Halonen family	155,172	44,999.88
Pekka Jalovaara	34,482	9,999.78
Jyrki Halonen	34,482	9,999.78
Jarmo Halonen	34,482	9,999.78
<b>Total</b>	<b>1,401,142</b>	<b>406,331.18</b>

The Company has not received or requested collaterals from the parties that have committed to subscribe for the Offer Shares in the Offering on the basis of subscription undertakings.

#### **Availability of certain documents**

A copy of this supplement will be kept available in electronic form on the Company's website <https://www.bbs-artebone.fi/investors/share-issue-2024-9/>, and copies of them may be viewed at the Company's main offices at Kiviharjunlenkki 6, FI-901220 Oulu during normal office hours.